Alpha-GPC Reference

Plain English

What it is

Alpha-GPC is a choline compound that comes from the same building blocks as fats in the brain. In the US it is sold as a dietary supplement, not as an FDA-approved drug, though in some other countries it is a prescription medicine for memory problems. It gives the body choline, which the brain uses to make acetylcholine, a signaling chemical tied to memory and learning.

What people use it for

People take it hoping to sharpen thinking, memory, and focus. Some athletes use it hoping to boost strength or power output before training. In the nootropic community it is often paired with racetams as a choline source.

What the science shows

Most of the human research is small and of mixed quality. A few short trials in people who already have memory impairment show a modest benefit, but no studies show it improves thinking in healthy people, so the everyday brain-boosting claims are largely unproven. A small exercise study found a short-term gain in lower-body force, which is far from settled.

The catch

Because it is a supplement, its quality and labeling are not vetted by the FDA the way prescription drugs are. Side effects are usually mild, such as heartburn, headache, dizziness, or trouble sleeping, and no large long-term safety studies exist. One very large 10-year study linked alpha-GPC use to a higher risk of stroke, so the safety picture is not fully clear.

Reference summary

Italian clinical literature in cognitive impairment / vascular dementia. Smaller US literature in athletic-performance / power-output trials.

Regulatory and posture

Categories

Nootropic, Cognitive

Aliases

L-alpha glycerylphosphorylcholine, Choline alfoscerate

Evidence posture

human - Sold as a dietary supplement in the US, not as an FDA-approved drug. Effects on cognition or power output are studied in small trials with mixed quality. Not a treatment.

Regulatory status

No FDA-approved alpha-GPC drug label in the US. Sold as a dietary supplement (FDA-NDI on file) and as a prescription drug in some non-US markets (e.g., Italy under Gliatilin) for cognitive impairment.

Content review status

research reference

Related tools

• Protocol builder overview - Public overview of the Pro protocol builder.